- Home
- IHS vs AUPH Comparison
IHS vs AUPH Comparison
Compare IHS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- AUPH
- Stock Information
- Founded
- IHS 2001
- AUPH 1993
- Country
- IHS United Kingdom
- AUPH Canada
- Employees
- IHS N/A
- AUPH N/A
- Industry
- IHS Telecommunications Equipment
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- IHS Telecommunications
- AUPH Health Care
- Exchange
- IHS Nasdaq
- AUPH Nasdaq
- Market Cap
- IHS 1.1B
- AUPH 1.3B
- IPO Year
- IHS 2021
- AUPH 1999
- Fundamental
- Price
- IHS $3.24
- AUPH $9.03
- Analyst Decision
- IHS Strong Buy
- AUPH Strong Buy
- Analyst Count
- IHS 6
- AUPH 3
- Target Price
- IHS $9.42
- AUPH $10.33
- AVG Volume (30 Days)
- IHS 514.4K
- AUPH 1.5M
- Earning Date
- IHS 11-12-2024
- AUPH 02-13-2025
- Dividend Yield
- IHS N/A
- AUPH N/A
- EPS Growth
- IHS N/A
- AUPH N/A
- EPS
- IHS N/A
- AUPH N/A
- Revenue
- IHS $1,783,187,000.00
- AUPH $220,361,000.00
- Revenue This Year
- IHS N/A
- AUPH $36.97
- Revenue Next Year
- IHS $1.75
- AUPH $16.43
- P/E Ratio
- IHS N/A
- AUPH N/A
- Revenue Growth
- IHS N/A
- AUPH 38.72
- 52 Week Low
- IHS $2.18
- AUPH $4.71
- 52 Week High
- IHS $4.79
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- IHS 55.36
- AUPH 51.75
- Support Level
- IHS $2.96
- AUPH $9.22
- Resistance Level
- IHS $3.39
- AUPH $9.76
- Average True Range (ATR)
- IHS 0.16
- AUPH 0.44
- MACD
- IHS -0.02
- AUPH -0.10
- Stochastic Oscillator
- IHS 47.06
- AUPH 16.33
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, most of who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.